Melanoma News and Research

Latest Melanoma News and Research

Combination molecules with BRAF inhibitors may help overcome drug resistance in melanoma patients

About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer. Most of these patients respond well to two novel agents being studied in clinical trials that inhibit the gene, with remarkable responses that are, unfortunately, almost always limited in duration.

3 Aug 2011

Positive results from Jennerex JX-594 proof-of-concept trial on metastatic melanoma

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that positive results from a proof-of-concept clinical trial using JX-594 to treat patients with metastatic melanoma were published in the peer-reviewed journal Molecular Therapy.

2 Aug 2011

Drink wine to prevent sunburns: Flavonoid research

According to a new Spanish study wine could protect against harmful sunburns. The researchers from the University of Barcelona and the Spanish National Research Council find that a compound found in grapes or grape derivatives may protect skin cells from skin-damaging ultraviolet radiation.

1 Aug 2011

Skin cancer vaccine on the way: Cancer expert Prof Ian Frazer

In a major medical breakthrough, cancer expert Prof Ian Frazer is on the verge of developing a vaccine against skin cancer within a year. The former ‘Australian of the Year’ and creator of the world's first cervical cancer vaccine, Gardasil, has developed a world-first strategy to combat the insidious disease that affects two out of three Australians.

31 Jul 2011

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Amgen reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010. Total product sales increased 8 percent in the second quarter of 2011 to $3,893 million versus $3,613 million in the second quarter of 2010. The increase in total revenue in the second quarter of 2011 included a decline in other revenue due to certain milestone payments earned in the second quarter of 2010.

29 Jul 2011

Studies reveal new set of mutations linked with head and neck cancer

Powerful new technologies that zoom in on the connections between human genes and diseases have illuminated the landscape of cancer, singling out changes in tumor DNA that drive the development of certain types of malignancies such as melanoma or ovarian cancer.

29 Jul 2011

Polaris initiates ADI-PEG 20 Phase 3 trial in hepatocellular carcinoma

Polaris Group today announced that it has dosed the first patient in a pivotal Phase 3 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in hepatocellular carcinoma (HCC) patients.

29 Jul 2011

Celgene reports second quarter total revenue of $1.18 billion

Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69.

28 Jul 2011

Adaptimmune announces opening of pilot clinical trial in synovial sarcoma

Adaptimmune announced today that it has opened a Pilot, open-label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland, testing its enhanced T cell receptor T cell therapy. A second site is planned to open later this year at Washington University, St. Louis, Missouri.

25 Jul 2011

Affordable cell transfer therapy for cancers

One of the latest attempts to boost the body's defenses against cancer is called adoptive cell transfer, in which patients receive a therapeutic injection of their own immune cells. This therapy, currently tested in early clinical trials for melanoma and neuroblastoma, has its limitations: Removing immune cells from a patient and growing them outside the body for future re-injection is extremely expensive and not always technically feasible.

25 Jul 2011

Genesis Biopharma partners with Lonza for Contego to treat metastatic melanoma

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, and Lonza, today announced the signing of a process development and scale-up agreement relating to the manufacture of Contego™, Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.

25 Jul 2011

Taller women more prone to cancer: Study

New research has shown that taller women could be more prone to suffering from cancer. The British study published online in the medical journal The Lancet on Thursday said cancer risk rose about 16% for every 4-inch rise in height. Increasing height heightened the chances of cancers of breast, ovary, womb, bowel, leukemia and malignant melanoma (skin cancer) the study found.

21 Jul 2011

Galectin, University of Michigan enter collaboration to study role of Galectins in cardiovascular disease

Galectin Therapeutics Inc. today announced that it has entered into a research collaboration with Dr. Jose Jalife of the University of Michigan Medical School to better understand the relationship of Galectin-3 to cardiac fibrosis in chronic cardiac arrhythmias.

21 Jul 2011

BioSante announces worldwide license of Melanoma Vaccine to Hussman Foundation

BioSante Pharmaceuticals, Inc., today announced an exclusive worldwide license of its Melanoma Vaccine to The John P. Hussman Foundation, a charitable foundation that supports research to address life-threatening medical conditions and significant disabilities.

21 Jul 2011

High methodological quality studies of PET in malignant melanoma patients needed

The relevance of positron emission tomography (PET) alone or in combination with computed tomography (CT) in patients with malignant melanoma cannot be currently assessed due to a lack of meaningful studies. This is the result of a final report published by the German Institute for Quality and Efficiency in Health Care (IQWiG) on 20 July 2011.

21 Jul 2011

Receptor GPR56 could have a critical role in cancer progression

Melanoma is devastating on many fronts: rates are rising dramatically among young people, it is deadly if not caught early, and from a biological standpoint, the disease tends to adapt to even the most modern therapies, known as VEGF inhibitors.

21 Jul 2011

Loyola medical experts offer heat and pollution advisory prescriptions

Many across the nation are experiencing the "dog days of summer" and medical experts at Gottlieb Memorial Hospital, part of Loyola University Health System, warn residents to take extra precautions to safeguard their health.

21 Jul 2011

Bristol-Myers Squibb announces results of BMS-708163 Phase II study on Alzheimer's

Bristol-Myers Squibb Company today announced the results of a Phase II study evaluating the safety and tolerability of the investigational gamma secretase inhibitor BMS-708163 in patients with mild-to-moderate Alzheimer's disease.

21 Jul 2011

Beta HPV prophylactic strategies may have a positive impact on prevention of NMSC

Non-melanoma skin cancer is the most common form of malignancy in adult Caucasian populations, with more than a million cases recorded each year in the USA alone.

21 Jul 2011

Experts available to discuss various effects of sun exposure

After many long winter months, Canadians are eager to get outside and enjoy the short and sweet season of warm summer sunshine. Although soaking up the sun can help us forget our winter blues, too much or unprotected exposure can have harmful consequences to your health.

15 Jul 2011